Stockpolly
Search
Delisting risk
QNCX · NASDAQ · Biotechnology

Quince Therapeutics (QNCX)

Develops inhaled sirolimus for pulmonary hypertension and bronchiolitis obliterans syndrome.

$31.61
Pre-market−0.94 (−2.89%)
At close$32.55(+1.37%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
681128610151013191180
Research & development1344568781375
5555445334417
General & administrative5055405334417
Other expenses00319−302023058
Operating income−6−8−11−28−6−10−15−10−13−19−11−80
1−1000−20−60−17424
Interest income111111000001
Other non-operating income01−3−1932−26−2−3−42−4
Income before tax−5−9−11−28−5−12−15−16−13−3631−75
Income tax expense0000000003−50
Net income from continuing operations−5−9−11−28−5−12−15−16−13−3936−75
Net income−5−9−11−28−5−12−15−16−13−3936−75
EPS, basic−$1.50−$44.00−$52.00−$128.00−$26.00−$56.00−$68.00−$68.00−$50.00−$150.00$143.40−$12.31
EPS, diluted−$1.50−$44.00−$52.00−$128.00−$26.00−$56.00−$68.00−$68.00−$50.00−$150.00$143.40−$12.31
Weighted average shares, basic400000000006
Weighted average shares, diluted400000000006
EBITDA−6−9−9−9−8−12−13−16−11−1631−75
Depreciation & amortization000000000000
EBIT−6−9−9−9−9−12−13−16−11−1631−75